The ophthalmic pharmaceutical companies Acuity Pharmaceuticals and the Froptix Corporation merge with eXegenics Inc. to form OPKO Health.
OPKO acquires the Chilean pharmaceutical distributor Pharma Genexx S.A., which marks the beginning of OPKO's Latin American presence.
OPKO acquires Mexican drug manufacturer and distributor Pharmacos Exakta, S.A. de C.V
OPKO and TESARO, Inc. sign an exclusive license agreement for the development and marketing of the oncology support drug, Rolapitant®
OPKO agrees to sell its ophthalmic instrumentation business to OPTOS, Inc.
OPKO acquires microfluidics based diagnostic test system developer, Claros Diagnostics.
OPKO acquires FineTech Pharmaceutical Ltd., an Israeli company which develops and produces high value, high potency active pharmaceutical ingredients (APIs).
OPKO acquires the rights to a kallikrein based prostate cancer diagnosis test from Arctic Partners Ab Oy. This test would become a key component of OPKO's 4Kscore® prostate cancer risk assessment laboratory developed test.
OPKO acquires Spanish pharmaceutical, nutraceutical and veterinary product company, Farmadiet Group Holding, S.L.
OPKO acquires Cytochroma Inc. and their lead nephrology products, Rayaldee® (calcifediol) and Alpharen®.
OPKO acquires PROLOR Biotech, with platform technologies to extend the biological half-life of therapeutic proteins and peptides. This technology is used in OPKO's late clinical stage product Somatrogon©, for the treatment of growth hormone deficiency (GHD), and in a Factor VIIa product for the treatment of hemophilia A & B.
OPKO launches the 4Kscore® test in the United States (U.S). The 4Kscore® test is a laboratory developed test and is suggested to be used after an elevated prostate specific antigen (PSA) test result to risk stratify the detection of aggressive prostate cancer.
OPKO presents data demonstrating that the 4Kscore® is an accurate, sensitive, and personalized predictor of high-grade prostate cancer at the American Urological Association Plenary Session.
OPKO launches the 4Kscore® test in Europe.
OPKO and Pfizer Inc. enter into a strategic partnership for the development and commercialization of OPKO’s long-acting human growth hormone, Somatrogon©.
OPKO acquires EirGen Pharma (Eirgen), Ireland. EirGen specializes in the development and manufacturing of high potency pharmaceutical products.
OPKO acquires the full service clinical laboratory, BioReference Laboratories, Inc.
OPKO subsidiary GeneDx demonstrates that whole exome sequencing can provide a definitive diagnosis for patients with rare and complex genetic conditions.
OPKO and Vifor Fresenius Medical Care Renal Pharma entered into a collaboration and license agreement for the development and commercialization of Rayaldee® (calcifediol) in Europe, Canada, Mexico, Australia, South Korea and other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency.
The U.S Food and Drug Administration (FDA) approves a New Drug Application (NDA) for Rayaldee® (calcifediol) extended release capsules for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency, defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
OPKO acquires the Canadian biopharmaceutical company Transitions Therapeutics Inc. and its products in clinical development.
OPKO enters into the animal health market with the launch of its line of U.S veterinary pharmaceuticals and nutraceuticals.
OPKO enters into an exclusive agreement with Japan Tobacco Inc. (JT) for the development and commercialization of Rayaldee® in Japan.
OPKO's strategic partner Vifor Fresenius receives marketing approval for Rayaldee® in Canada.
OPKO announces FDA approval for the point-of-care Sangia PSA Test with the Claros® 1 Analyzer.